Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali

  title={Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of K{\'e}ni{\'e}roba, a Malaria Endemic Village in Mali},
  author={Karim Traore and Seidina A. S. Diakit{\'e} and S{\'e}kou Bah and Drissa S. Konat{\'e} and Djeneba Dabitao and Ibrahima Sanogo and Modibo Sangare and Souleymane Dama and Bourama Keita and Mory Doumbouya and Merepen A. Guindo and Seydou Doumbia and Mahamadou Diakit{\'e}},
  journal={Drugs in R\&D},
  pages={249 - 255}
In 2006, the National Malaria Control Program in Mali recommended artemisinin-based combination therapy as the first-line treatment for uncomplicated malaria. Since the introduction of artemisinin-based combination therapy, few reports are available on the level of resistance of Plasmodium falciparum to the most common anti-malarial drugs in Mali. From 2016 to 2017, we assessed the ex-vivo drug sensitivity of P. falciparum isolates in Kéniéroba, a village located in a rural area of southern… 


Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study
The results of this study indicate that an intensive surveillance of the in vitro P. falciparum susceptibility to anti-malarial drugs must be conducted in Senegal.
Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs
The introduction of ACT in 2002 has not induced a decrease in P. falciparum susceptibility to the drugs DHA, MDAQ and LMF, which are common ACT components, however, the prevalence of the in vitro resistant isolates with reduced susceptibility has increased for both MQ and DOX.
Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015
An increase in the reduced susceptibility to monodesethylamodiaquine observed in 2014 in Dakar and the chloroquine resistance observed in 2013 is confirmed, confirming the in vitro resistance seems to be established in Senegal.
Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali
Malian post-AL P. falciparum isolates were less susceptible to artemether and lumefantrine than baseline isolates, and three non-synonymous K13-propeller SNPs were found with allele frequencies <2%.
Plasmodium falciparum isolates from southern Ghana exhibit polymorphisms in the SERCA-type PfATPase6 though sensitive to artesunate in vitro
The pfATPase6 gene is highly polymorphic with D639G appearing to be fixed in Ghanaian isolates, however, there is no improvement in susceptibility of the parasites to chloroquine five years after its proscription.
Correlation of in vitro sensitivity of chloroquine and other antimalarials with the partner drug resistance to Plasmodium falciparum malaria in selected sites of India
A positive correlation between in vitro drug resistance with molecular markers for antimalarial drug resistance could make in vitro assay a reliable tool to predict drug efficacy which is needed for detection of emerging resistance in the country.
Return of chloroquine sensitivity to Africa? Surveillance of African Plasmodium falciparum chloroquine resistance through malaria imported to China
The results suggest that a reduction in drug pressure following withdrawal of CQ as a first-line drug may lead to a resurgence in CQ sensitive parasites.
[In vitro susceptibility of P. falciparum isolates from Abidjan (Côte d'Ivoire) to quinine, artesunate and chloroquine].
This work sought to establish a national map of drug resistance by using in vitro tests with clinical surveys to detect changes in susceptibility and to prevent the emergence of resistance against the most recently introduced combined therapy.